Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries.
Jessie Narloch(Duke Medical Center), Kimberly Blackwell(Duke University), Carey K. Anders(Duke University), Peter E. Fecci(University of Colorado Anschutz Medical Campus), Nolan Priedigkeit(University of Pittsburgh), Adrian V. Lee(Baylor College of Medicine), Shannon Leigh Huggins-Puhalla(UPMC Hillman Cancer Center), Adam Brufsky(University of Pittsburgh), José Pablo Leone(Harvard University), Terry Hyslop(Thomas Jefferson University), Catherine Luedke(Duke Medical Center), Matt Ewend(Northwestern University), John P. Kirkpatrick(Duke University), Allison Hall(Duke Medical Center), Juanita Ramirez(University of North Carolina at Chapel Hill), Gloria Broadwater, Sarah Sammons(Dana-Farber Cancer Institute)
Cited by 5
Related Papers
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
|International Journal of Radiation Oncology*Biology*Physics|2009|984